CSL

CSL EBIT per Employee

The EBIT per Employee of CSL (CSL.AX) as of Oct 26, 2026 is 163,962.44 USD. In the previous year, EBIT per Employee was 134,760.00 USD — a change of 21.67% (higher).

EBIT per Employee

163,962.44USD

YoY

21.67%

Last updated:

EBIT per Employee of CSL is 2026 163,962.44 USD. EBIT per Employee of CSL was 2025 134,760.00 USD. It decreases by 21.67% higher compared to the previous year.

The CSL EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2019
93,287.32 USD
Jan 1, 2020
98,645.16 USD
Jan 1, 2021
110,276.00 USD
Jan 1, 2022
99,068.00 USD
Jan 1, 2023
100,320.00 USD
Jan 1, 2024
128,040.00 USD
Jan 1, 2025
134,760.00 USD
Jan 1, 2026
163,962.44 USD
The CSL EBIT per Employee history
YEAREBIT per EmployeeYoY
163,962.44USD+21.67%
134,760.00USD+5.25%
128,040.00USD+27.63%
100,320.00USD+1.26%
99,068.00USD-10.16%
110,276.00USD+11.79%
98,645.16USD+5.74%
93,287.32USD+5.27%
88,613.14USD+25.74%
70,470.74USD+61.76%
43,564.00USD-31.29%
63,403.30USD+0.97%
62,793.85USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CSL stock

EBIT per Employee of CSL is 163,962.44 USD in 2026.

EBIT per Employee of CSL changed from 134,760.00 USD to 163,962.44 USD, representing a 21.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee CSL since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's CSL historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — CSL

All Key Metrics — CSL